Safety considerations in the use of ganciclovir in immunocompromised patients.
DeArmond
B
B
Department of Immunology and Antiviral Therapy II, Syntex Research, Palo Alto, California 94303.
D003404:Creatinine; D003587:Cytomegalovirus / Q000187:drug effects; D004352:Drug Resistance, Microbial; D015774:Ganciclovir / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D007108:Immune Tolerance; D007668:Kidney / Q000187:drug effects; D009503:Neutropenia / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced
D003404:Creatinine; D015774:Ganciclovir